Chardan Capital Weighs in on OCUL FY2025 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Ocular Therapeutix in a research note issued to investors on Wednesday, October 15th. Chardan Capital analyst D. Gataulin forecasts that the biopharmaceutical company will post earnings per share of ($1.45) for the year. Chardan Capital currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. Chardan Capital also issued estimates for Ocular Therapeutix’s FY2026 earnings at ($0.99) EPS.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The company had revenue of $13.46 million for the quarter, compared to the consensus estimate of $13.12 million. Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.Ocular Therapeutix’s quarterly revenue was down 17.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.26) EPS.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Wednesday, October 8th. Scotiabank cut their price objective on Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating for the company in a research report on Wednesday, August 6th. Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Wednesday, October 1st. Needham & Company LLC lifted their price objective on Ocular Therapeutix from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Finally, Zacks Research upgraded Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 2nd. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $22.63.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $11.77 on Monday. The business has a 50 day simple moving average of $12.21 and a 200 day simple moving average of $10.10. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.10 and a quick ratio of 10.02. Ocular Therapeutix has a one year low of $5.78 and a one year high of $13.85. The company has a market capitalization of $2.05 billion, a PE ratio of -9.20 and a beta of 1.45.

Institutional Investors Weigh In On Ocular Therapeutix

Institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its position in shares of Ocular Therapeutix by 62.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,604 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,392 shares during the last quarter. Brooklyn Investment Group increased its holdings in Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 3,155 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 893 shares during the last quarter. GAMMA Investing LLC increased its holdings in Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 8,112 shares during the last quarter. Finally, Trust Co. of Vermont increased its holdings in Ocular Therapeutix by 16.1% in the second quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Insider Transactions at Ocular Therapeutix

In other news, insider Todd Anderman sold 11,132 shares of the business’s stock in a transaction on Wednesday, October 8th. The stock was sold at an average price of $12.34, for a total transaction of $137,368.88. Following the completion of the sale, the insider owned 87,568 shares in the company, valued at $1,080,589.12. The trade was a 11.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jeffrey S. Heier sold 10,502 shares of the business’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $11.04, for a total value of $115,942.08. Following the sale, the insider owned 249,409 shares of the company’s stock, valued at approximately $2,753,475.36. The trade was a 4.04% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 61,806 shares of company stock worth $727,648. Insiders own 2.30% of the company’s stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.